Rain Oncology Inc. (NASDAQ:RAIN – Get Rating) – Equities research analysts at Oppenheimer issued their FY2027 earnings estimates for Rain Oncology in a research report issued on Sunday, April 9th. Oppenheimer analyst J. Jones anticipates that the company will post earnings per share of $6.24 for the year. The consensus estimate for Rain Oncology’s current […]
Related Keywords
United States , , Goldman Sachs Group Inc , Rain Oncology Inc , Millennium Management , Rain Therapeutics Inc , Renaissance Technologies , Morgan Stanley , Nasdaq , Rain Oncology Company Profile , Thrivent Financial For Lutherans , Rain Oncology , Get Rating , Oncology Stock Down , Sachs Group , Thrivent Financial , Therapeutics Inc , Rain Oncology Daily , Nasdaq Rain , Rain , Medical , Earnings Estimates , Oppenheimer Holdings Inc ,
comparemela.com © 2020. All Rights Reserved.